Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration

Sponsor
Saglik Bilimleri Universitesi
Study ID
NCT07235527
Status
Recruiting
Apply to this trial

Conditions

  • Age Related Macular Degeneration
  • Anti Vascular Endothelial Growth Factor
  • Exudative Age-Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
45 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.

Key Dates

Start date
Nov 20, 2025
Status verified
Dec 2025
Primary completion
Jun 20, 2026
Completion
Aug 20, 2026

Study Design

Enrollment
54 participants (estimated)

Arms

  • Arm: patients treated with Yesafili
    aflibercept biosimilar used

Primary Outcome Measure

Change in Best-Corrected Visual Acuity (BCVA) and Central Macular Thickness After MY-1701P Injection [ Time Frame: Baseline to Month 6 ]

Central Contacts

Related Studies